Cell Therapeutics, Inc. Announces Filing of Form 10-K

SEATTLE, March 28 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) today announced that the filing of its annual report on
Form 10-K for the year ended December 31, 2007 has now been timely completed.
This filing is available for review on CTI's Web site at
www.CellTherapeutics.com or on the Securities and Exchange Commission's
Web site at www.sec.gov.
As required under Nasdaq Marketplace Rule 4350(b)(1)(B), CTI also
announced that its independent auditor's report included in the annual report
on Form 10-K contains a "going concern" qualification.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to
developing an integrated portfolio of oncology products aimed at making cancer
more treatable. For additional information, please visit
www.CellTherapeutics.com.
Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: media@ctiseattle.com
here

Investors Contact:
Leah Grant
T: 206.282.7100
F: 206.272.4434
E: invest@ctiseattle.com
here

SOURCE Cell Therapeutics, Inc.

media, Dan Eramian, +1-206-272-4343, cell, +1-206-854-1200,
media@ctiseattle.com, or investors, Leah Grant, +1-206-282-7100, fax,
+1-206-272-4434, invest@ctiseattle.com, both of Cell Therapeutics, Inc.